Mild plaque-type psoriasis Marijuana, Cannabis, Cannabidiol, Calcipotriol, Triamcinolone, Plaque-type psoriasis, Cost
Conditions
Interventions
CBD ointment of different concentrations will be used
Experimental Drug
CBD ointment
Sponsors
Institute of dermatology, Ministry of public health
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Male or female diagnosed with mild plaque-type psoriasis 2. Age 18-60 years 3. Otherwise healthy 4. Willing to participate and can come for scheduled follow-ups
Exclusion criteria
Exclusion criteria: 1. Have acute skin inflammation/infection which is not psoriasis 2. Have been treated with topical tar-containing products, vitamin A and vitamin D derivatives, corticosteroids, UVB phototherapy withinthe previous two weeks 3. Have been treated with oral vitamin A derivatives, corticosteroids, cyclosporine, methotrexate, PUVA phototherapy or laser therapy within the previous 4 weeks 4. Have been treated with immunosuppressants such as alefacept, etanercept, infliximab, efalizumab or adalimumab within the previous 12 weeks 5. Have other diseases or currently taking other drugs which may interfere with normal skin function and with this study such as beta-blocker, lithium, oral contraceptive pill, ACE inhibitor, antimalarial, NSAIDS, interferon, imiquimod, gemfibrozil 6. Have a history of allergy to cannabis/cannabis products, steroids, vitamin D derivatives 7. Pregnant of breast-feeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy 2 months ESI/IGA score | — |
Secondary
| Measure | Time frame |
|---|---|
| cost-effectiveness 2 month cost-effectiveness analysis | — |
Countries
Thailand
Contacts
Public ContactChanisa Kiatsurayanon
Institute of dermatology
Outcome results
None listed